News & Updates

Clinical Announcement | News | Press Releases
InCarda Therapeutics Announces Results From the RESTORE-1 Phase 3 Trial and Plans for Continued Development
Read More
News | Press Releases
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
Read More
News | Press Releases
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
Read More
Events | News
InCarda Presents Additional Phase 2 Data for InRhythm (Orally Inhaled Flecainide) at the 2022 European Society of Cardiology Congress in Barcelona
Read More
News | Press Releases
InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation
Read More
Events | News
InCarda Presents Phase 2 Safety and Efficacy Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Heart Rhythm Society Conference in San Francisco
Read More
Events
Mick Hurrey, VP of Product Development will be presenting at RDD on May 3, 2022
Read More
News
InCarda Therapeutics Announces Publication of Phase 2 Data Demonstrating Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm Is Safe and Effective
Read More
Publications
Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm
Read More
Events | News
InCarda Presents Phase 2 Data for InRhythm (Orally Inhaled Flecainide) at the 2022 Atrial Fibrillation Symposium in New York
Read More
Events | News
Grace Colón recognized by the Biotechnology Innovation Organization as one of 25 Hispanic Trailblazers to Know in Science and Biotech
Read More
Events | News
Luiz Belardinelli, Chief Medical Officer will be presenting at the Chief Medical Officer Summit 360˚ on Oct 14, 2021
Read More

We’re proud to share what’s new.

Sign up to be the first to learn about new developments.

We respect your email privacy